Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043329 · ClinicalTrials.gov registry record
Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
A clinical trial of Osteopetrosis, sponsored by InterMune.
- Completed
- Registry status
- 6
- Enrollment target
- 1
- Study location
NCT00043329 is a study of Osteopetrosis that has completed, run by InterMune. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00043329, a study of Osteopetrosis, has completed, sponsored by InterMune.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish a registry of all children with severe, malignant osteopetrosis who are treated with Actimmune (IFN-g 1b or Interferon gamma-1b) to monitor the effects of IFN-g 1b on preventing progression of this disease and to follow the safety of patients receiving it on a long-term basis. In addition, evaluation of the possible effect of Actimmune therapy on the humoral response to normal childhood vaccinations in this same patient population will be examined.Interferon gamma is a substance that the body makes naturally.
Conditions Studied
Interventions
- DRUG Actimmune Registry
Study Locations (1)
California
- InterMune, Inc. - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2002-01 |
| Est. Completion | 2005-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043329
The ClinicalTrials.gov registry entry for NCT00043329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteopetrosis appearing as the primary indexed condition, and to 1 intervention - of which Actimmune Registry is the first listed.
NCT00043329 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00043329 about?
NCT00043329 is a clinical study titled "Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis". The purpose of this study is to establish a registry of all children with severe, malignant osteopetrosis who are treated with Actimmune (IFN-g 1b or Interferon gamma-1b) to monitor the effects of IFN-g 1b on preventing progression of this disease and to follow the safety of patients receiving it on...
What is the current status of trial NCT00043329?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2002-01. Estimated completion is 2005-09.
What conditions does trial NCT00043329 study?
This clinical trial studies the following conditions: Osteopetrosis.
What interventions are being tested in trial NCT00043329?
The interventions under investigation include: Actimmune Registry (DRUG).
Who is sponsoring clinical trial NCT00043329?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043329 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteopetrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.